DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+10.83%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$2.99B
AUM Growth
+$2.99B
(-2.3%)
Cap. Flow
-$245M
Cap. Flow
% of AUM
-8.2%
Top 10 Holdings %
Top 10 Hldgs %
35.72%
Holding
154
New
30
Increased
26
Reduced
34
Closed
30
Top Buys
| 1 |
Viatris
VTRS
|
$58.4M |
| 2 |
ALPN
Alpine Immune Sciences, Inc. Common Stock
ALPN
|
$56.5M |
| 3 |
Teva Pharmaceuticals
TEVA
|
$38.2M |
| 4 |
DYAX
DYAX CORPORATION
DYAX
|
$35.8M |
| 5 |
Galapagos
GLPG
|
$33.1M |
Top Sells
| 1 |
ASPX
AUSPEX PHARMACEUTICALS INC COM STK (DE)
ASPX
|
$446M |
| 2 |
AbbVie
ABBV
|
$89.8M |
| 3 |
Adverum Biotechnologies
ADVM
|
$85.8M |
| 4 |
BLUE
bluebird bio
BLUE
|
$51.3M |
| 5 |
ACHN
Achillion Pharmaceuticals, Inc.
ACHN
|
$27.7M |
Sector Composition
| 1 | Healthcare | 71.13% |
| 2 | Financials | 3.44% |
| 3 | Technology | 0.52% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Travere Therapeutics
TVTX
$1.75B
| – | – |
-158,223
| Closed | -$3.79M |
|
127
Tempest Therapeutics
TPST
$46.6M
| – | – |
-407,108
| Closed | -$14.1M |
|
128
Nektar Therapeutics
NKTR
$543M
| – | – |
-45,600
| Closed | -$502K |
|
129
MEI Pharma
MEIP
$149M
| – | – |
-802,568
| Closed | -$1.44M |
|
130
Illumina
ILMN
$15.2B
| – | – |
-6,400
| Closed | -$1.19M |
|
131
Gilead Sciences
GILD
$140B
| – | – |
0
| – | – |
|
132
Exelixis
EXEL
$9.95B
| – | – |
0
| – | – |
|
|
CLLS
133
Cellectis
CLLS
$260M
| – | – |
-150,506
| Closed | -$5.2M |
|
134
Cross Country Healthcare
CCRN
$420M
| – | – |
-366,724
| Closed | -$4.35M |
|
135
Alkermes
ALKS
$4.95B
| – | – |
-17,500
| Closed | -$1.07M |
|
|
136
Adverum Biotechnologies
ADVM
$68.2M
| – | – |
-2,117,473
| Closed | -$85.8M |
|
137
Acadia Pharmaceuticals
ACAD
$4.34B
| – | – |
-49,400
| Closed | -$1.61M |
|
138
Abbott
ABT
$230B
| – | – |
-13,000
| Closed | -$602K |
|
139
Abeona Therapeutics
ABEO
$356M
| – | – |
-349,908
| Closed | -$1.1M |
|
|
140
AbbVie
ABBV
$374B
| – | – |
-1,534,000
| Closed | -$89.8M |
|